GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (XPAR:IVA) » Definitions » Debt-to-Revenue

Inventiva (XPAR:IVA) Debt-to-Revenue : 641.11 (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Inventiva Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Inventiva's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €5.73 Mil. Inventiva's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €46.85 Mil. Inventiva's annualized Revenue for the quarter that ended in Jun. 2024 was €0.08 Mil. Inventiva's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 641.11.


Inventiva Debt-to-Revenue Historical Data

The historical data trend for Inventiva's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inventiva Debt-to-Revenue Chart

Inventiva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 27.03 2.41 2.83 2.15

Inventiva Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 138.30 1.43 9.24 1.20 641.11

Competitive Comparison of Inventiva's Debt-to-Revenue

For the Biotechnology subindustry, Inventiva's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inventiva's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inventiva's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Inventiva's Debt-to-Revenue falls into.



Inventiva Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Inventiva's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.308 + 32.181) / 17.477
=2.15

Inventiva's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.726 + 46.845) / 0.082
=641.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.


Inventiva Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Inventiva's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Inventiva Business Description

Traded in Other Exchanges
Address
50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.